Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

NeoStem Moves Forward on China Biopharma Acquisition

publication date: Oct 8, 2009

NeoStem, Inc. reported the SEC accepted its registration proposal to acquire China Biopharmaceutical Holdings in an all-stock transaction. China Biopharma’s only asset is a 51% interest in Suzhou Erye Pharmaceutical Co., a generic drug manufacturer that in 2008 produced $50 million in revenues and net income of $8 million. More details...

Stock Symbols: (NYSE Amex: NBS) (OTCBB: CHBP)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital